ATE521627T1 - Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins - Google Patents
Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteinsInfo
- Publication number
- ATE521627T1 ATE521627T1 AT05808971T AT05808971T ATE521627T1 AT E521627 T1 ATE521627 T1 AT E521627T1 AT 05808971 T AT05808971 T AT 05808971T AT 05808971 T AT05808971 T AT 05808971T AT E521627 T1 ATE521627 T1 AT E521627T1
- Authority
- AT
- Austria
- Prior art keywords
- cross
- flavivirus
- reactive epitopes
- identification
- envelope glycoprotein
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title abstract 5
- 101710121417 Envelope glycoprotein Proteins 0.000 title 1
- 102100021696 Syncytin-1 Human genes 0.000 title 1
- 206010057199 Flaviviral infections Diseases 0.000 abstract 1
- 230000009260 cross reactivity Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59189804P | 2004-07-27 | 2004-07-27 | |
| PCT/US2005/026672 WO2006025990A2 (en) | 2004-07-27 | 2005-07-27 | Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521627T1 true ATE521627T1 (de) | 2011-09-15 |
Family
ID=36000491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05808971T ATE521627T1 (de) | 2004-07-27 | 2005-07-27 | Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7906292B2 (de) |
| EP (1) | EP1784487B1 (de) |
| AT (1) | ATE521627T1 (de) |
| CA (1) | CA2576798C (de) |
| IN (1) | IN2012DN03294A (de) |
| WO (1) | WO2006025990A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2524975T3 (es) | 2009-07-31 | 2014-12-16 | Ge Healthcare Bio-Sciences Corp. | Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células |
| CA2836501A1 (en) * | 2011-07-12 | 2013-01-17 | Gwong-Jen J. Chang | Identification of a west nile virus cd4 t cell epitope and use thereof |
| WO2013059493A1 (en) | 2011-10-20 | 2013-04-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
| WO2014064943A1 (en) * | 2012-10-25 | 2014-05-01 | Osaka University | Antigenic peptide derived from dengue virus |
| BR112015032388A8 (pt) | 2013-06-26 | 2020-01-14 | Univ North Carolina Chapel Hill | glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições |
| US10060924B2 (en) | 2014-03-18 | 2018-08-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
| CN107405392B (zh) * | 2015-02-09 | 2021-05-18 | 中央研究院 | 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗 |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| ES2937963T3 (es) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| GB201610162D0 (en) * | 2016-06-10 | 2016-07-27 | Imp Innovations Ltd And Inst Pasteur | Methods |
| CA3026807A1 (en) | 2016-06-13 | 2017-12-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays |
| WO2018052549A1 (en) | 2016-09-19 | 2018-03-22 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Zika virus vaccines |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018152526A1 (en) | 2017-02-20 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Zika virus vaccines |
| GB201704126D0 (en) * | 2017-03-15 | 2017-04-26 | Blom Nihlén Kim Andrea | Vaccine |
| US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
| CN111048154B (zh) * | 2019-12-10 | 2023-06-06 | 上海药明生物技术有限公司 | 一种抗体表位作图的方法 |
| JP2023546048A (ja) * | 2020-10-07 | 2023-11-01 | サノフィ・パスツール | 改良された診断試験 |
| WO2023178310A1 (en) * | 2022-03-17 | 2023-09-21 | The University Of North Carolina At Chapel Hill | Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK172110B1 (da) * | 1988-04-15 | 1997-10-27 | Gen Hospital Corp | Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner |
| US6074865A (en) * | 1995-07-20 | 2000-06-13 | The United States Of America As Represented By The Secretary Of The Army | Recombinant dengue virus DNA fragment |
| US6869793B2 (en) * | 1996-09-24 | 2005-03-22 | Bavarian Nordic Research Institute | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| CU22683A1 (es) * | 1997-01-15 | 2001-07-20 | Inst De Medicina Tropical Pedro Kouri | Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos |
| BRPI9701774B8 (pt) * | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
| US7227011B2 (en) | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| IL139844A0 (en) | 1998-06-04 | 2002-02-10 | Us Gov Health & Human Serv | Nucleic acid vaccines for prevention of flavivirus infection |
| WO2005056600A2 (en) * | 2003-12-08 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize dengue virus |
-
2005
- 2005-07-27 EP EP05808971A patent/EP1784487B1/de active Active
- 2005-07-27 AT AT05808971T patent/ATE521627T1/de not_active IP Right Cessation
- 2005-07-27 US US11/572,805 patent/US7906292B2/en active Active
- 2005-07-27 WO PCT/US2005/026672 patent/WO2006025990A2/en active Application Filing
- 2005-07-27 CA CA2576798A patent/CA2576798C/en active Active
- 2005-07-27 IN IN3294DEN2012 patent/IN2012DN03294A/en unknown
-
2010
- 2010-09-28 US US12/892,714 patent/US9000141B2/en active Active
-
2015
- 2015-03-16 US US14/659,251 patent/US9650422B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150246951A1 (en) | 2015-09-03 |
| IN2012DN03294A (de) | 2015-10-23 |
| US7906292B2 (en) | 2011-03-15 |
| US9000141B2 (en) | 2015-04-07 |
| WO2006025990A3 (en) | 2006-06-29 |
| EP1784487A2 (de) | 2007-05-16 |
| CA2576798C (en) | 2014-09-09 |
| US9650422B2 (en) | 2017-05-16 |
| US20080248064A1 (en) | 2008-10-09 |
| US20110059131A1 (en) | 2011-03-10 |
| WO2006025990A2 (en) | 2006-03-09 |
| CA2576798A1 (en) | 2006-03-09 |
| EP1784487B1 (de) | 2011-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE521627T1 (de) | Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins | |
| Simmons et al. | Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. | |
| MA29406B1 (fr) | Vaccin toxoide alpha de c. perfringens | |
| GB2438802A (en) | Structure of the hepatitis C virus NS5A protein | |
| NO20072253L (no) | Forbedrede vaksiner | |
| DE602004020189D1 (de) | Adjuvante influenza-vakzine | |
| ATE497492T1 (de) | Reinigung von montelukast | |
| WO2007064742A3 (en) | Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus (prrsv) and uses thereof | |
| ATE542829T1 (de) | Impfstoff | |
| EA201170353A1 (ru) | Антитела против гепатита с и их применение | |
| NO20072470L (no) | Malariaigangsetter/forsterkervaksine | |
| ATE490262T1 (de) | Abschwächung der immunogenizität von fusionsproteinen | |
| EP1504112A4 (de) | Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten | |
| DK1255815T3 (da) | Porcint reproduktivt og respiratorisk syndromvirus til fremgangsmåder til anvendelse | |
| TW200512457A (en) | Method of diagnosing SARS corona virus infection | |
| DK0996717T3 (da) | Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination | |
| WO2006041866A3 (en) | Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes | |
| NO20063026L (no) | Antistoffer | |
| NZ585777A (en) | Compositions and methods of enhancing immune responses to eimeria | |
| WO2005012337A3 (en) | Antigenic peptides of sars coronavirus and uses thereof | |
| DK1409692T3 (da) | Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine | |
| MX2011006846A (es) | Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv. | |
| ATE520713T1 (de) | Identifizierung und veränderung von immundominanten polypeptidepitopen | |
| WO2006050219A3 (en) | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies | |
| EA201100071A1 (ru) | Новые композиции и способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |